Industry news that matters to you.  Learn more

N-of-One Selected by Admera Health to Provide Clinical Interpretation for the OncoGxOne 64-Gene Oncology Panel

N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, recently announced that Admera Health, a molecular diagnostics company focused on personalized medicine and non-invasive cancer testing, has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne™. N-of-One’s patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient’s molecular tests to therapeutic strategies, including clinical trials. Financial terms of the agreement are not disclosed.

Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific

Invivoscribe® Technologies, Inc., a global company that provides international access to personalized molecular diagnostics, today announces it has signed a long-term strategic collaboration agreement with Thermo Fisher Scientific to develop multiple next-generation sequencing (NGS)-based, in vitro diagnostic (IVD) oncology tests on the Ion PGMTM Dx System.

Edico Genome Collaborates with Intel to Overcome Big Data Bottleneck in Next-Generation Sequencing

Edico Genome recently announced a collaboration with Intel Corporation to develop solutions with Intel’s Xeon processors to accelerate next generation sequencing (NGS) data analysis. The resulting solution will enable completion of primary and secondary NGS analysis in real time, while sustaining superior accuracy, decreasing costs, streamlining data analysis in the cloud and holds benefits for applications that require sharing of big data sets, such as analysis of population-scale genomic data.

Edico Genome’s DRAGEN Bio-IT Processor Enhances PerkinElmer’s Next-Generation Sequencing Workflow

Edico Genome recently announced that PerkinElmer, Inc. has purchased a DRAGEN™ Bio-IT processor to expedite the analysis of its customers’ next-generation sequencing (NGS) data. Applying the processor to PerkinElmer’s NGS workflow, DRAGEN accelerates analysis time for whole genome and whole exome sequencing 60 fold, compared to standard industry software, while maintaining greater than 99 percent sensitivity. The processor will be integrated into PerkinElmer’s CLIA-certified, high-throughput sequencing facility.

CompanionDx Launches NGS-based Cancer Assays Using GenomOncology’s GO Clinical Workbench

CompanionDx Reference Lab, LLC, a high-complexity CLIA-certified laboratory specializing in pharmacogenomics, cancer companion diagnostics and targeted next-generation sequencing (NGS), recently announced it is offering a series of NGS-based assays related to cancer. To enable efficient and compliant clinical reporting from NGS, CompanionDx chose to partner with GenomOncology, an Ohio-based genomics technology and services provider.